SCHEMBL7188947

SCHEMBL7188947

CC(C)Oc1ccc(PC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(OC(C)C)c1.[LiH]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
PDK2 Q15119 1/20 0.38
PTPN5 P54829 1/20 0.36
KCNK3 O14649 1/20 0.34
KCNK9 Q9NPC2 1/20 0.34
SCN8A Q9UQD0 1/20 0.34
SCN10A Q9Y5Y9 1/20 0.34
ALDH1A1 P00352 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34
FFAR4 Q5NUL3 1/20 0.33
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
ALOX12 P18054 1/20 0.33
CCR6 P51684 1/20 0.33
KMT2A Q03164 1/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
P2RX7 Q99572 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7188957 0.98 RXRA (0.40) RXRARXRBRXRGPDK2PTPN5
SCHEMBL7182795 0.88 MRGPRX4 (0.34) RXRARXRBRXRGSCN8ASCN10A
SCHEMBL7182439 0.88 PDK2 (0.38) RXRARXRBRXRGPDK2PTPN5
SCHEMBL7187115 0.87 RXRA (0.40) RXRARXRBRXRGPDK2PTPN5
SCHEMBL7177812 0.86 MRGPRX4 (0.33) RXRARXRBRXRGPDK2KCNK3
SCHEMBL7188855 0.85 FFAR1 (0.33) RXRARXRBRXRGKCNK3KCNK9
Lithium SCHEMBL7177817 0.84 MRGPRX4 (0.33) RXRARXRBRXRGPDK2KCNK3
SCHEMBL7180569 0.83 MAPT (0.44) ALDH1A1MEN1GAAMAPTKMT2A
SCHEMBL7190032 0.83 RORC (0.37) RXRARXRBALDH1A1MEN1GAA
SCHEMBL7181619 0.83 POLB (0.39) RXRARXRBRXRGPDK2PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 RXRA 2745/4885RXRB 3027/4885RXRG 2912/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 RXRA 2809/4885RXRB 3240/4885RXRG 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.